To Examine the Effects of Axitinib Dose Reduction and Interruption for Adverse Event Management Among Patients Receiving Axitinib in for the Treatment of Advanced Renal Cell Carcinoma

NCT04682587 · clinicaltrials.gov ↗

COMPLETED

Status

481

Enrollment

INDUSTRY

Sponsor class

Conditions

Renal Cell Carcinoma

Interventions

DRUG: Axitinib
DRUG: Avelumab
DRUG: Pembrolizumab

Sponsor

Pfizer